Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Many core opioid safety and pharmacology claims are supported by the provided NUCYNTA label sections (e.g., addiction/abuse/misuse, respiratory depression, neonatal opioid withdrawal syndrome, CNS depressant interactions). However, numerous other claims are non-label content (manufacturer/patent site/pricing/market competition/generic expectations) or broad instructions/comparative statements not supported by the label text provided, reducing overall alignment.
Category Scores
Accurate Statements
Nucynta is an opioid pain medication.
Supported by indication for use of an opioid analgesic for acute pain (Indications and Usage) and opioid risks in Warnings and Precautions (5.1).
Nucynta is an opioid analgesic.
Indications and Usage (1) and Warnings context (5.1).
Nucynta carries significant risks including potential for addiction, abuse, and misuse.
Warnings and Precautions (5.1).
Nucynta misuse can lead to overdose and death.
Warnings and Precautions (5.1) describing increased risk of opioid-related overdose and overdose-related death.
Nucynta can cause respiratory depression.
Warnings and Precautions (5.2).
Nucynta can cause neonatal opioid withdrawal syndrome.
Warnings and Precautions (5.4).
Nucynta has interactions with other central nervous system depressants.
Warnings and Precautions (5.3) and Drug Interactions (7) / Warnings and Precautions (5.16) describing additive effects with alcohol and other CNS depressants.
Nucynta's active ingredient is tapentadol.
Contains tapentadol (5.1) and Descriptions/Clinical Pharmacology (11/12.1).
Tapentadol acts as a mu-opioid receptor agonist.
Mechanism of Action (12.1) and Description (11).
Tapentadol acts as a norepinephrine reuptake inhibitor.
Mechanism of Action (12.1) and Description (11).
Tapentadol has a dual mechanism of action as a mu-opioid receptor agonist and a norepinephrine reuptake inhibitor.
Mechanism of Action (12.1).
Clinical trials have evaluated Nucynta for management of moderate to severe acute pain.
Clinical Studies (14.1) describing moderate to severe pain studies including acute pain context.
Clinical trials for Nucynta compare it against placebo or other active treatments.
Clinical Studies (14.1) describing placebo- and active-controlled studies.
Unsupported Statements
Nucynta is manufactured by Depomed, Inc.
Manufacturer attribution is not present in the provided label sections.
Patient assistance programs offered by the manufacturer or pharmaceutical companies can provide free or low-cost medication to eligible individuals.
Not found in the provided label sections.
Nucynta's patent expiration dates may involve multiple patents related to the drug's composition, manufacturing, and method of use.
Patent/expiration specifics are not present in the provided label sections.
DrugPatentWatch.com tracks patent information for pharmaceuticals.
External website description not included in label content.
A search on DrugPatentWatch.com for Nucynta (tapentadol hydrochloride) reveals various patents.
External search results are not included in the provided label sections.
Some Nucynta patents are expected to expire in the coming years.
No label-supported timing/expectations about patent expiration are provided.
Generic versions of Nucynta typically become available as patents for branded medications expire.
General patent/generic availability statements are not present in the provided label sections.
Availability of generic Nucynta would depend on expiration of relevant patents and regulatory approval by the U.S. Food and Drug Administration (FDA).
No label-supported statements about patent dependencies or FDA approval gating for generic availability.
Generic drugs are usually priced lower than their brand-name counterparts.
No label-supported pricing statements are provided.
Nucynta should be used only as prescribed.
No label instruction with this exact broad phrasing is supported by the provided label sections.
Nucynta competes in the pain management market with other opioid analgesics.
Market/commercial competition statements are not present in the label.
Nucynta competes in the pain management market with non-opioid pain relief medications.
Market/commercial competition statements are not present in the label.
Competitors can include other extended-release opioid formulations.
Market framing/competitor examples are not present in the label.
Competitors can include alternative classes of drugs used for moderate to severe pain.
Market framing/competitor examples are not present in the label.
This dual mechanism differentiates tapentadol from some other opioids that primarily target only the mu-opioid receptor.
The provided label does not include comparative differentiation against other opioids.
The specific efficacy, side effect profile, and risk of dependence can vary among different pain relief medications.
No label-supported general comparative statement.
Clinical trials typically assess Nucynta's efficacy in pain reduction.
The provided label supports existence of efficacy studies but does not provide this general 'typically assess' statement as written.
Clinical trials typically assess Nucynta's safety and tolerability profile.
The provided label indicates safety evaluation but does not provide this general 'typically assess' statement as written.
Contradictions
Important Omissions
Dosage and administration details (e.g., dosing regimen, titration, pediatric age/weight specifics, conversion guidance) were not addressed by the AI claims set.
Importance:
Moderate
No contraindication statements were evaluated/provided in the AI claims set.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While key opioid safety risks (addiction/abuse/misuse, respiratory depression, neonatal opioid withdrawal syndrome, and CNS depressant interactions) are supported, multiple label-nonfactual statements (patents/generics/pricing/market/administrative assertions) and unsupported broad instruction statements reduce labeling fidelity and could mislead users if treated as authoritative label content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several statements are not supported by the provided FDA label text (e.g., manufacturer attribution, patient assistance programs, patent site/expiration/generic pricing/market competition, and broad 'use only as prescribed' and comparative differentiation claims).
Suggested Improvement
Restrict claims to labeling-supported content (indication, opioid risk warnings, respiratory depression guidance, neonatal opioid withdrawal syndrome, and described CNS depressant/additive interaction warnings/mechanism). Remove external/patent/pricing/market assertions and avoid comparative or broadly worded instructions unless explicitly present in the label text provided.